Author(s)

Ankita Jain^1*, Kumar Prabhash², Venkatraman Radhakrishnan³, Shashank Srinivasan¹

¹Pfizer Products India Private Limited, Mumbai, India.
²Tata Memorial Hospital, Mumbai, India.
³Cancer Institute (W.I.A.), Chennai, India.

Studies reporting the Indian prevalence of Epidermal Growth Factor Receptor (EGFR) mutation are mostly single centers with small sample sizes. This systematic review and meta-analysis summarized the available evidence of EGFR mutation epidemiology in Indian patients with adenocarcinoma (ADC) Non-Small Cell Lung Cancer (NSCLC). We conducted a structured literature search in PubMed, and EMBASE databases from January 2004 through October 2019. The primary outcome of interest was prevalence of EGFR mutation by gender, smoking status, and mutation subtype. The review included 34 studies. EGFR mutation prevalence was 39.5% in patients with ADC, and significantly higher in females, non-smokers, and patients with exon 19 deletions. The EGFR mutation frequency in Indian patients with ADC was higher than reported in Caucasians but at a lower range of that reported in East Asians. These findings support the use of EGFR mutation testing to guide choice of treatment.

Epidemiology, Epidermal Growth Factor Receptor, Adenocarcinoma, Non-Small Cell Lung Cancer, India

Jain, A. , Prabhash, K. , Radhakrishnan, V. and Srinivasan, S. (2024) Epidemiology of EGFR Mutation in Adenocarcinoma NSCLC Patients in India: A Systematic Review and Meta-Analysis. Advances in Lung Cancer, 13, 1-21. doi: 10.4236/alc.2024.131001.